Understanding pancreatic cancer

Written in association with: Mr Nikolaos Chatzizacharias
Published: | Updated: 30/10/2024
Edited by: Carlota Pano

Pancreatic cancer is one of the most challenging malignancies to diagnose and treat, often presenting with few specific symptoms until it has reached advanced stages. Early detection is thus crucial for improving patient outcomes.

 

Mr Nikolaos Chatzizacharias, renowned consultant hepato-pancreato-biliary and liver transplant surgeon, will explore the symptoms and staging of pancreatic cancer, along with the different treatment options available, including surgery.

 

 

What is pancreatic cancer?

 

The pancreas is a large gland situated behind the stomach in the back of the abdomen. It produces hormones, including insulin, which regulates blood sugar levels, as well as pancreatic juices that contain vital enzymes.

 

Normally, cells in the body, including those in the pancreas, grow in a controlled manner. However, sometimes, this control breaks down, causing cells to begin growing uncontrollably. These cells subsequently create a mass referred to as cancer.

 

There are different types of pancreatic cancer. The most prevalent types of pancreatic cancer, which make up about 80% of all cases, originate from the cells lining the pancreatic ducts and are referred to as pancreatic ductal adenocarcinoma.

 

What are the symptoms of pancreatic cancer?

 

In its early stages, pancreatic cancer typically doesn’t cause many noticeable symptoms, making it difficult to diagnose. If symptoms do present, they may include:

 

How is pancreatic cancer diagnosed?

 

When you present symptoms that raise concerns for pancreatic cancer, the initial tests typically include blood tests. These are often followed by an ultrasound scan. The most effective test for diagnosing pancreatic cancer is a CT scan with contrast, administered through a cannula in the arm. Other tests, such as MRI or PET scans, may also be utilised to help in diagnosis and staging. If the diagnosis remains unclear, an endoscopic ultrasound and a biopsy of the mass will be necessary.

 

Additionally, it’s essential to classify cancers by stage at the time of diagnosis. Your multidisciplinary cancer team, which will consist of specialists from various fields (including oncologists, surgeons, and radiologists) will create an individualised treatment plan based on your specific cancer stage. Among the different staging systems for pancreatic cancer, the most common one divides cancer into four stages. In stage 4, the cancer has metastasised, meaning it has spread to distant organs in the body.

 

Following cancer staging, the system widely-used for guiding treatment decisions in pancreatic cancer is from the USA National Comprehensive Cancer Network, which categorises pancreatic cancers into those confined to the pancreas and those that are metastatic.

 

Cancers that haven’t metastasised are further classified as "resectable," "borderline resectable," or "locally advanced", based on the tumour's involvement with the major blood vessels near the pancreas. Tumours that don’t involve any vessels, or only lightly touch the major veins, are considered "resectable." If the tumour involves the large vessels more extensively, it’s classified as either "borderline resectable" or "locally advanced," based on the extent of involvement.

 

What treatment options are available for pancreatic cancer?

 

Treatment options for pancreatic cancer include surgery, chemotherapy, radiotherapy, and various clinical trials. The choice of treatment will depend on the stage of your cancer, along with your overall health and medical history. In certain cases, treatments may be given in combination.

 

For pancreatic cancer classified as “resectable,” the first-line treatment is surgery, followed by chemotherapy. When chemotherapy is given after surgery, this is known as “adjuvant chemotherapy.”

 

In instances where pancreatic cancer is categorised as “borderline resectable” or “locally advanced,” chemotherapy is the first treatment. This is then known as “neoadjuvant chemotherapy.” After three to six months of chemotherapy (as determined by your multidisciplinary cancer team), further investigations will be conducted. Based on these results, your hepato-pancreato-biliary surgeon will assess whether surgery is possible, which will need to be scheduled within 4 to 6 weeks following the completion of neoadjuvant treatment.

 

What are the different types of surgical options?

 

There are three main types of operations for pancreatic cancer, based on the specific area of the pancreas affected and the involvement of nearby organs or major blood vessels.

 

Pancreaticoduodenectomy (classical or pylorus-preserving)

A pancreaticoduodenectomy is the standard procedure for tumours situated in the head of the pancreas. During this surgery, your hepato-pancreato-biliary surgeon will remove the head of the pancreas, the duodenum, 15-20 cm of the small intestine, the gallbladder, and a portion of the bile duct.

In the classical pancreaticoduodenectomy, the distal portion of the stomach will also be removed, whereas in the pylorus-preserving pancreaticoduodenectomy, the stomach will be left intact. Afterward, the remaining pancreas, bile duct, and stomach will be reconnected to the intestine.

 

Distal pancreatectomy and splenectomy

A distal pancreatectomy and splenectomy is the usual surgery performed for tumours in the body and tail of the pancreas. During this surgery, your hepato-pancreato-biliary surgeon will remove the tail and body of the pancreas, as well as the surrounding tissues.

Additionally, the spleen will also be taken out. This is done for two reasons: first, the blood vessels supplying the spleen are positioned adjacent to the body and tail of the pancreas, and second, the lymph nodes that must be removed to eliminate any cancer are closely linked to the spleen.

 

Total pancreatectomy and splenectomy

In some cases, a total pancreatectomy will be required to ensure the complete removal of pancreatic cancer. This procedure integrates aspects of both the pancreaticoduodenectomy and the distal pancreatectomy with splenectomy.

 

Why is selecting your doctors important for a good outcome?

 

The management of pancreatic cancer is a complex undertaking that is, therefore, better delivered by specialist multidisciplinary teams that regularly manage such cases. Furthermore, evidence supports that surgery for pancreatic cancer achieves better outcomes when the operation is performed in a high-volume centre, with pancreatic surgery having been centralised in the UK for many years now.

 

However, even with measures within the speciality, not all aspects of surgical treatment are offered everywhere, and expertise can vary widely within specialist centres and surgical teams. These variations in experience are most notable in cases of "borderline resectable" and "locally advanced" tumours, when operating after neoadjuvant chemotherapy and on major vessels is crucial for a successful outcome. 

 

During these operations, techniques to separate the tumour from large veins and arteries, or to resect these vessels and reconnect them to the circulation, are usually required and are not widely practised. Therefore, identifying and selecting a surgeon with substantial experience is highly recommended.

 

 

If you would like to book an appointment with Mr Nikolaos Chatzizacharias, head on over to his Top Doctors profile today.

By Mr Nikolaos Chatzizacharias
Surgery

Mr Nikolaos Chatzizacharias is a distinguished consultant hepato-pancreato-biliary and liver transplant surgeon based in Birmingham. His areas of expertise include locally advanced pancreatic cancer, cholangiocarcinoma (bile duct cancer), liver cancer, gallbladder surgery, and complex resections. He is highly proficient in both open and minimally invasive surgical procedures, as well as robotic surgery.

Mr Chatzizacharias consults privately at The Harborne Hospital. He is also the lead for the Locally Advanced Pancreatic Cancer Programme at Queen Elizabeth Hospital in Birmingham, recognised as the largest of its kind in the UK. Since 2017, he also practises at University Hospitals Birmingham NHS Foundation Trust.

With over 20 years’ experience, Mr Chatzizacharias originally qualified from the National and Kapodistrian University of Athens, where he earned an MD and later achieved a PhD in pancreatic cancer research. Mr Chatzizacharias undertook basic surgical training in Oxford, before going on to complete higher specialist training in upper gastrointestinal, hepato-pancreato-biliary, transplant surgery on the prestigious East of England and University of Cambridge rotation.

Mr Chatzizacharias notably accomplished a fellowship in hepato-pancreato-biliary surgery at the Medical College of Wisconsin. He also holds esteemed fellowship to both The Royal College of Surgeons of England and The American College of Surgeons. His commitment to advancing treatment options for pancreatic cancer has made him a leader in his field.

In addition to his clinical work, Mr Chatzizacharias is active in research, with numerous peer-reviewed publications and presentations at national and international conferences. He holds an honorary associate clinical professor position at the University of Birmingham, and he also serves as the principal investigator for the DISSECT trial, which investigates the role of periadventitial dissection in improving surgical margins during resectable pancreatic cancer surgery.

View Profile

Overall assessment of their patients


  • Related procedures
  • Mouth cancer
    Prostate cancer
    Human papillomavirus (HPV)
    Human papillomavirus vaccine (HPV)
    Breast cancer
    Brain tumour
    Testicular cancer
    Thyroid cancer
    Adrenal glands cancer
    Doppler Ultrasound
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.